Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

May 14, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

ATL administration

Subjects have ATL administration using intravenous infusion

Trial Locations (13)

111

NOT_YET_RECRUITING

Shin Kong Wu Ho Su Memorial Hospital, Taipei

333

RECRUITING

Chang Gung Memorial Hospital, Linkou, Taoyuan District

10341

RECRUITING

Taipei City Hospital, RENAI Branch, Taipei

23148

NOT_YET_RECRUITING

Cardinal Tien Hospital, New Taipei City

73657

NOT_YET_RECRUITING

Chi Mei Hospital, Liouying, Tainan City

82445

RECRUITING

E-Da Cancer Treatment Hospital, Kaohsiung City

97002

RECRUITING

Hualien Tzu Chi Hospital, Hualien City

100225

RECRUITING

National Taiwan University Hospital, Taipei

110301

RECRUITING

Taipei Medical University Hospital, Taipei

112201

RECRUITING

Taipei Veterans General Hospital, Taipei

114202

RECRUITING

Tri-Service General Hospital, Taipei

220216

RECRUITING

Far Estern Memorial Hospital, New Taipei City

407219

NOT_YET_RECRUITING

Taichung Veterans General Hospital, Taichung

Sponsors
All Listed Sponsors
collaborator

Virginia Contract Research Organization Co., Ltd.

OTHER

lead

Lukas Biomedical Inc.

INDUSTRY

NCT05304481 - Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter